W. Todd Myers

Biography

    W. Todd Myers, C.P.A., is a veteran financial executive with significant management experience in both public and private drug discovery/development companies. Mr. Myers is currently a member of the Board of Advisors of BioLaurus, Inc., a contract research organization specializing in cutting edge molecular imaging and high content analysis services for the biotechnology and pharmaceutical industry. He also provides coaching and guidance to start-up life science companies as an Entrepreneur-in-Residence at CONNECT, a non-profit organization dedicated to creating and sustaining the growth of innovative technology and life science businesses in San Diego. Most recently, Mr. Myers was the Chief Financial Officer of SGX Pharmaceuticals, Inc., a publicly-traded biotechnology company focused on the discovery, development and commercialization of innovative cancer therapeutics, and was instrumental in the sale of SGX to Eli Lilly & Company at a premium of 119% to its then-current trading price. Prior to SGX, as the Director of Finance at CombiChem, Inc, a publicly-traded computational drug discovery company, Mr. Myers managed all financial operations and was the senior financial representative on the team responsible for the sale of the company to DuPont Pharmaceuticals. He was also the Chief Financial Officer of FeRx Incorporated, a privately-held, clinical stage company dedicated to the development of oncology products, and has held positions with Premier Inc. and with Ernst & Young LLP. Mr. Myers received his B.S. in Accounting from the University of Illinois.  

Research Interest

    Biomedical Sciences